Combinations for the treatment of cancer
AssigneeIgnyta, Inc.
InventorsGang Li, Ge Wei, Zachary D. Hornby, Jonathan Ee-ren Lim
Life of this patent
Estimating the term…
Abstract
Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.
Claims15
A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a combination comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and the second agent is a MEK inhibitor selected from the group consisting of PD0325901, selumetinib, cobimetinib, refametinib, trametinib, pimasertib, binimetinib, AZD8330, R04987655, GDC-0623, TAK-733, sorafenib, and PD-184352;
- the cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer, melanoma, and colorectal cancer;
- the patient has at least one mutation in the TrkA receptor tyrosine kinase polypeptide;
- and the at least one mutation in the TrkA receptor tyrosine kinase polypeptide is at a position corresponding to amino acid residue G595 or G667 of the TrkA polypeptide set forth in SEQ ID NO:
- 1.
A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a combination comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and the second agent is a MEK inhibitor selected from the group consisting of PD0325901, selumetinib, cobimetinib, refametinib, trametinib, pimasertib, binimetinib, AZD8330, R04987655, GDC-0623, TAK-733, sorafenib, and PD-184352;
- the cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer, melanoma, and colorectal cancer;
- the patient has at least one mutation in the TrkB receptor tyrosine kinase polypeptide;
- and the at least one mutation in the TrkB receptor tyrosine kinase polypeptide is at a position corresponding to amino acid residue G639 or G709 of the TrkB polypeptide set forth in SEQ ID NO:
- 2.
A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a combination comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and the second agent is a MEK inhibitor selected from the group consisting of PD0325901, selumetinib, cobimetinib, refametinib, trametinib, pimasertib, binimetinib, AZD8330, R04987655, GDC-0623, TAK-733, sorafenib, and PD-184352;
- the cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer, melanoma, and colorectal cancer;
- the patient has at least one mutation in the TrkC receptor tyrosine kinase polypeptide;
- and the at least one mutation in the TrkC receptor tyrosine kinase polypeptide is at a position corresponding to amino acid residue G623 or G696 of the TrkC polypeptide set forth in SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.